BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial. American Journal of Kidney Diseases 2007;50:989-1000. [DOI: 10.1053/j.ajkd.2007.08.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opinion on Pharmacotherapy 2009;10:1509-14. [DOI: 10.1517/14656560902997982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
3 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60. [PMID: 22536082 DOI: 10.2147/IJNRD.S23447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
5 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
6 Charytan C. Bundled-Rate Legislation for Medicare Reimbursement for Dialysis Services: Implications for Anemia Management with ESAs. CJASN 2010;5:2355-62. [DOI: 10.2215/cjn.04820610] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol 2010;50:507-20. [PMID: 20179322 DOI: 10.1177/0091270009343931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
8 Choy BY, Lam MF, Yip T, Tang HL, Wong PN, Chow CCV, Yap DY, Chan TM. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients: C.E.R.A. use in Chinese dialysis patients. Nephrology 2013;18:533-8. [DOI: 10.1111/nep.12105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 El-Komy MH, Schmidt RL, Widness JA, Veng-Pedersen P. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep. Biopharm Drug Dispos 2011;32:276-88. [PMID: 21678432 DOI: 10.1002/bdd.757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
10 Bamgbola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 2012;27:195-205. [PMID: 21424525 DOI: 10.1007/s00467-011-1839-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
11 Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. Br J Clin Pharmacol 2020;86:801-11. [PMID: 31770451 DOI: 10.1111/bcp.14186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Duman N, Uyanik A, Unsal A, Sezer S, Camsari T, Cirit M, Yilmaz ME, Altun B, Duranay M, Yildiz A, Sahin I, Dogukan A, Ustundag S, Karayaylali I, Kahveci A, Sindel S, Kiykim AA, Yenicerioglu Y, Akbas E, Ozdener F. Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Clin Kidney J 2014;7:464-9. [PMID: 25504109 DOI: 10.1093/ckj/sfu079] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-49. [PMID: 18345959 DOI: 10.1517/14656566.9.5.839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
14 Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R; on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2008;24:348-54. [DOI: 10.1093/ndt/gfn653] [Cited by in Crossref: 129] [Cited by in F6Publishing: 94] [Article Influence: 9.2] [Reference Citation Analysis]
15 Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 2014;29:76-83. [PMID: 24431909 DOI: 10.3346/jkms.2014.29.1.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
17 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Heidenreich S, Leistikow F, Zinn S, Baumann J, Atzeni A, Bajeski V, Dietzmann J, Dragoun GP; SUPRA Study Group. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig 2012;32:99-110. [PMID: 22117178 DOI: 10.2165/11594040-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Moreira F, Carmo H, Guedes de Pinho P, Bastos ML. Doping detection in animals: A review of analytical methodologies published from 1990 to 2019. Drug Test Anal 2021;13:474-504. [PMID: 33440053 DOI: 10.1002/dta.2999] [Reference Citation Analysis]
20 Ryckelynck JP. [Change of hemoglobin level: causes and consequences. Renal anemia]. Nephrol Ther 2008;4 Spec No 2:9-16. [PMID: 19000893 DOI: 10.1016/S1769-7255(08)74251-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 2011;26:1303-10. [PMID: 21416403 DOI: 10.1007/s00467-011-1846-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
22 Pérez-Ruixo JJ, Cucala-Ramos M, García-Gonzalo E, Del Val Romero B, Valveny N. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. Br J Clin Pharmacol 2013;75:15-25. [PMID: 22803621 DOI: 10.1111/j.1365-2125.2012.04383.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
23 Mikhail A, Shrivastava R, Richardson D. Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease. Nephron Clin Pract 2011;118:c101-24. [DOI: 10.1159/000328063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Kacarska-Fotevska II, Volckova N, Ilievska K, Donev D. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience. Med Arch 2020;74:109-14. [PMID: 32577051 DOI: 10.5455/medarh.2020.74.109-114] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15(37): 4675-4685 [PMID: 19787831 DOI: 10.3748/wjg.15.4675] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
27 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
28 Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73:117-30. [PMID: 23338536 DOI: 10.1007/s40265-012-0002-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
29 Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol 2010;6:218-23. [DOI: 10.1038/nrneph.2010.19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
30 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
31 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
33 Ezziani M, Najdi A, Mikou S, Hanin H, Arrayhani M, Houssaini TS. [Predictors of response to the CERA in chronic hemodialysis treatment-naive by erythropoiesis-stimulating agent]. Pan Afr Med J 2015;20:331. [PMID: 26175821 DOI: 10.11604/pamj.2015.20.331.4467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis. J Nephrol 2018;31:321-32. [DOI: 10.1007/s40620-017-0419-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
35 Novak JE, Szczech LA. Triumph and tragedy: anemia management in chronic kidney disease: . Current Opinion in Nephrology and Hypertension 2008;17:580-8. [DOI: 10.1097/mnh.0b013e32830c488d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
36 Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473-1485. [PMID: 22849511 DOI: 10.1517/14712598.2012.711308] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
37 Macdougall IC. Development of Recombinant Erythropoietin and Erythropoietin Analogs. Textbook of Nephro-Endocrinology. Elsevier; 2018. pp. 217-32. [DOI: 10.1016/b978-0-12-803247-3.00013-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Zabaneh R, Roger SD, El-Shahawy M, Roppolo M, Runyan G, O'Neil J, Qiu P. Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis. Perit Dial Int 2015;35:481-9. [PMID: 24584613 DOI: 10.3747/pdi.2012.00224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]